K
Ken Nakagawa
Researcher at Japanese Foundation for Cancer Research
Publications - 142
Citations - 7934
Ken Nakagawa is an academic researcher from Japanese Foundation for Cancer Research. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 37, co-authored 134 publications receiving 7390 citations. Previous affiliations of Ken Nakagawa include Kitasato University.
Papers
More filters
Journal ArticleDOI
RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi,Manabu Soda,Yuki Togashi,Ritsuro Suzuki,Seiji Sakata,Satoko Hatano,Reimi Asaka,Wakako Hamanaka,Hironori Ninomiya,Hirofumi Uehara,Young Lim Choi,Yukitoshi Satoh,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Hiroyuki Mano,Hiroyuki Mano,Yuichi Ishikawa +17 more
TL;DR: A multivariate analysis of 1,116 adenocarcinomas containing 71 kinase-fusion–positive adenokcinomas identified four independent factors that are indicators of poor prognosis: age ≥50 years, male sex, high pathological stage and negative kinase -fusion status.
Journal ArticleDOI
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi,Young Lim Choi,Yuki Togashi,Manabu Soda,Satoko Hatano,Kentaro Inamura,Shuji Takada,Toshihide Ueno,Yoshihiro Yamashita,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Yuichi Ishikawa,Hiroyuki Mano +13 more
TL;DR: An intercalated antibody-enhanced polymer (iAEP) method that incorporates an intercalating antibody between the primary antibody to ALK and the dextran polymer-based detection reagents should prove suitable for immunohistochemical screening of tumors positive for ALK or ALK fusion proteins among pathologic archives.
Journal ArticleDOI
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi,Young Lim Choi,Manabu Soda,Kentaro Inamura,Yuki Togashi,Satoko Hatano,Munehiro Enomoto,Shuji Takada,Yoshihiro Yamashita,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Yuichi Ishikawa,Hiroyuki Mano +13 more
TL;DR: A multiplex reverse transcription-PCR system is developed that captures all in-frame fusions between EML4 to exon 20 of ALK to reinforce the importance of accurate diagnosis of E ML4-ALK–positive tumors for the optimization of treatment strategies.
Journal ArticleDOI
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Kentaro Inamura,Kengo Takeuchi,Yuki Togashi,Kimie Nomura,Hironori Ninomiya,Michiyo Okui,Yukitoshi Satoh,Sakae Okumura,Ken Nakagawa,Manabu Soda,Young Lim Choi,Toshiro Niki,Hiroyuki Mano,Yuichi Ishikawa +13 more
TL;DR: In the present first investigation of EML4-ALK fusion in a large study of lung cancers, an interesting histotype-genotype relationship is found and the fusion protein could be detected by immunohistochemistry, pointing to possible clinical applications.
Journal ArticleDOI
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.
Kentaro Inamura,Kengo Takeuchi,Yuki Togashi,Satoko Hatano,Hironori Ninomiya,Noriko Motoi,Mingyon Mun,Yukinori Sakao,Sakae Okumura,Ken Nakagawa,Manabu Soda,Young Lim Choi,Hiroyuki Mano,Yuichi Ishikawa +13 more
TL;DR: EML4-ALK-positive tumors may form a distinct entity among lung adenocarcinomas, characterized by young onset, acinar histology, no or rare mutations in EGFR, KRAS, and TP53, and a TTF-1 cell lineage, all in agreement with the prevalence in non- or light smokers.